Absci Collaborates with Oracle and AMD to Speed up AI-Led Drug Discovery, Shares Jump

Tiger Newspress
09/11

Absci on Thursday announced a collaboration with Oracle Cloud Infrastructure and AMD to accelerate its AI-driven drug discovery efforts.

Absci shares jumped 9.5 in morning trading.

As part of the partnership, the Vancouver, Washington-based biotech will use Oracle’s AI infrastructure and AMD’s hardware for its generative AI Drug Creation Platform.

“This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows,” CEO Sean McClain remarked.

The announcement coincided with the Oracle Health and Life Sciences Summit taking place in Orlando, Florida, from Sept. 9 to 11.

During the event, the tech giant highlighted some of its healthcare-related advancements, including its AI capabilities within the Oracle Fusion Cloud Application, which it said could streamline supply chain operations within the industry.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10